Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 15/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | TYK2 | P29597 | 1/20 | 0.38 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.37 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL627636 | 0.70 | ABL1 (0.47) | NPC1RAB9ASMN1; SMN2ABL1 | |
| SCHEMBL15051493 | 0.64 | ABL1 (0.47) | NPC1RAB9ASMN1; SMN2ABL1 | |
| SCHEMBL15050990 | 0.63 | ABL1 (0.42) | ABL1PIK3C3 | |
| SCHEMBL15050787 | 0.63 | SMN1; SMN2 (0.36) | SMN1; SMN2ABL1 | |
| SCHEMBL15051050 | 0.62 | ABL1 (0.43) | NPC1RAB9ASMN1; SMN2ABL1PIK3C3 | |
| SCHEMBL9890572 | 0.62 | GSK3B (0.49) | ABL1ACVRL1 | |
| SCHEMBL15051872 | 0.62 | ABL1 (0.47) | NPC1RAB9ASMN1; SMN2ABL1 | |
| SCHEMBL15050904 | 0.62 | SMN1; SMN2 (0.35) | SMN1; SMN2ABL1JAK2TYK2PIK3C3 | |
| SCHEMBL15051283 | 0.62 | ABL1 (0.43) | ABL1PIK3C3 | |
| SCHEMBL15072582 | 0.61 | SMN1; SMN2 (0.36) | NPC1SMN1; SMN2ABL1JAK2TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859768-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-10-14 | — | — | US | disclosed |
| US-20120142732-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142732-A1 | HETEROARYLS AND USES THEREOF | PIK3R4, PIK3C2B, PIK3R1 | NPC1 91/4885RAB9A 109/4885SMN1; SMN2 4275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.